(Total Views: 137)
Posted On: 06/11/2021 8:30:48 AM
Post# of 36444
$BIO News Article - New Data Shows AbbVie's VENCLYXTO /VENCLEXTA Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment https://marketwirenews.com/news-releases/new-...73036.html
(0)
(0)
My Twitter: WhyteStocks
